Loading
A phase 3 trial of Iberdomide, Lenalidomide in multiple myeloma, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT05827016 by Bristol-Myers Squibb, with 1230 participants enrolled, started 2023-06-22 and due to reach its primary completion in 2029-03-15. Interventions recorded: Iberdomide, Lenalidomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Iberdomide, Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Iberdomide, Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.